Progress of bispecific antibodies in relapsed/refractory multiple myeloma

doi:10.3760/cma.j.issn.1007-1245.2023.03.006

Abstract

Abstract:

In recent years, monoclonal antibodies against specific surface antigens on multiple myeloma (MM) cells have been increasingly used to treat relapsed and refractory multiple myeloma (R/RMM). Bispecific antibodies (BsAb) combine with tumor cell antigens and CD3 on T cells to activate T cells and target tumor cells. There are a variety of BsAb targeted at B cell mature antigen (BCMA) targets and non BCMA targets, such as GPRC5D and FcRH5, showing their respective pharmacokinetic characteristics and related efficacy and adverse reactions. A number of clinical trials have confirmed that they have promising clinical efficacy and safety in R/RMM patients.

Key words:

Multiple myeloma, Bispecific antibodies, Immunotherapy, Target, Relapsed, Refractory

摘要：

近年来，针对多发性骨髓瘤（multiple myeloma，MM）细胞上特异性表面抗原的单克隆抗体越来越多应用于治疗复发难治多发性骨髓瘤（relapsed/refractory multiple myeloma，R/RMM）。双特异性抗体（bispecific antibodies，BsAb）与肿瘤细胞抗原和T细胞上的CD3结合，激活T细胞并靶向杀伤肿瘤细胞，有针对B细胞成熟抗原（B cell maturation antigen，BCMA）靶点和非BCMA靶点如GPRC5D和FcRH5的多种BsAb，显示各自的药代动力特点以及相关疗效和不良反应，多项临床试验研究已证实其在R/RMM患者中具有可喜的临床有效性和安全性。

关键词:

多发性骨髓瘤, 双特异性抗体, 免疫治疗, 靶向, 复发, 难治

Ling Juan, Zeng Huilan.

Progress of bispecific antibodies in relapsed/refractory multiple myeloma [J]. International Medicine and Health Guidance News, 2023, 29(3): 319-323.

凌娟曾慧兰.

双特异性抗体在复发难治多发性骨髓瘤中的治疗进展 [J]. 国际医药卫生导报, 2023, 29(3): 319-323.

References

[1] Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma[J]. Am J Hematol, 2022, 97suppl 1: S3-S25. DOI:10.1002/ajh.26512.
[2] Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-Targeted monoclonal antibody therapy[J]. Leukemia, 2019, 33(9): 2266-2275. DOI:10.1038/s41375-019- 0435-7.
[3] Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice[J]. Br J Haematol, 2016, 175(2): 252-264. DOI:10.1111/bjh.14213.
[4] Perez P, Hoffman RW, Shaw S, et al. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody[J]. Nature, 1985, 316(6026): 354-356. DOI:10.1038/316354a0.
[5] Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy[J]. Immunol Cell Biol, 2015, 93(3): 290-296. DOI:10.1038/icb.2014.93.
[6] Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies[J]. Blood, 2018, 131(1): 30-38. DOI:10.1182/blood-2017-06-741058.
[7] Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma[J]. BMJ, 2020, 370: m3176. DOI:10.1136/bmj.m3176.
[8] Seckinger A, Delgado JA, Moser S, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment[J]. Cancer Cell, 2017, 31(3): 396-410. DOI:10.1016/j.ccell.2017.02.002.
[9] Hipp S, Tai YT, Blanset D, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo[J]. Leukemia, 2017, 31(10): 2278. DOI:10.1038/leu.2017.219.
[10] Zhou X, Einsele H, Danhof S. Bispecific antibodies: a new era of treatment for multiple myeloma[J]. J Clin Med, 2020, 9(7): 2166. DOI:10.3390/jcm9072166.
[11] DiLillo DJ, Olson K, Mohrs K, et al. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells[J]. Blood Adv, 2021, 5(5): 1291-1304. DOI:10.1182/bloodadvances.2020002736.
[12] Topp MS, Duell J, Zugmaier G, et al. Anti-B-Cell maturation antigen bite molecule amg 420 induces responses in multiple myeloma[J]. J Clin Oncol, 2020, 38(8): 775-783. DOI:10.1200/JCO.19.02657.
[13] Cho SF, Lin L, Xing L, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models[J]. Blood Adv, 2020, 4(17): 4195-4207. DOI:10.1182/bloodadvances.2020002524.
[14] Cho SF, Lin L, Xing L, et al. AMG 701 potently induces anti-multiple myeloma (MM) functions of T cells and imids further enhance its efficacy to prevent mm relapse in vivo[J]. Blood, 2019, 134 suppl_1: 135. DOI:10.1182/blood-2019-128528.
[15] Madduri D, Rosko A, Brayer J, et al. REGN5458, a BCMA x CD3 bispecific monoclonal antibody, induces deep and durable responses in patients with relapsed/refractory multiple myeloma (RRMM)[J]. Blood, 2020, 136 suppl 1: 41-42. DOI:10.1182/blood-2020-139192.
[16] Chen H, Yu T, Lin L, et al. γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation[J]. Blood Cancer J, 2022, 12(8): 118. DOI:10.1038/s41408-022-00716-3.
[17] Usmani SZ, Garfall AL, van de Donk NWCJ, et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study[J]. Lancet, 2021, 398(10301): 665-674. DOI:10.1016/S0140-6736(21)01338-6.
[18] Usmani SZ, Mateos MV, Nahi H, et al. Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/RMM)[J]. J Clin Oncol, 2020, 38 15_suppl: 100. DOI:10.1200/JCO.2020.38.15_suppl.100.
[19] Karwacz K, Hooper AT, Chang CPB, et al. Abstract 4557: BCMA-CD3 bispecific antibody PF-06863135: preclinical rationale for therapeutic combinations[J]. Cancer Res, 2020, 80 16_suppl: 4557. DOI:10.1158/1538-7445.AM2020-4557.
[20] Bahlis NJ, Raje NS, Costello C, et al. Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma(MM)[C]. 2021 ASCO Annual Meeting, 2021.
[21] Sebag M, Raje N S, Bahlis NJ, et al. Elranatamab (PF-06863135), a b-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from magnetismm-1[J]. Blood, 2021, 138 suppl 1: 895. DOI:10.1182/blood-2021-150519.
[22] Levy M, Bahlis N, Raje N, et al. MM-379: MagnetisMM-1: a study of elranatamab (PF-06863135), a B-Cell maturation antigen (BCMA)-targeted, cd3-engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma (MM)[J]. Clin Lymphoma Myeloma Leuk, 2021, 21: S439. DOI:10.1016/S2152-2650(21)01978-9.
[23] Lesokhin AM, Raje N, Gasparetto CJ, et al. A phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity of PF-06863135, a B-cell maturation antigen/CD3 bispecific antibody, in patients with relapsed/refractory advanced multiple myeloma[J]. Blood, 2018, 132 suppl 1: 3229. DOI:10.1182/blood-2018-99-110427.
[24] Garfall AL, Usmani SZ, Mateos MV, et al. Updated phase 1 results of teclistamab, a B-Cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and/or refractory multiple myeloma (RRMM)[J]. Blood, 2020, 136 suppl 1: 27. DOI:10.1182/blood-2020-138831.
[25] Buelow B, Choudry P, Clarke S, et al. Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma[J]. J Clin Oncol, 2018, 36 15_suppl: 8034. DOI: 10.1200/JCO.2018.36.15_suppl.8034.
[26] Rodriguez C, D'Souza A, Shah N, et al. Initial results of a phase I study of TNB-383B, a BCMA x CD3 bispecific t-cell redirecting antibody, in relapsed/refractory multiple myeloma[J]. Blood, 2020, 136 suppl 1: 43-44. DOI:10.1182/blood-2020-139893.
[27] D'Souza A, Shah N, Rodriguez C, et al. A phase I first-in-human study of ABBV-383, a b-cell maturation antigen × cd3 bispecific t-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma[J]. J Clin Oncol, 2022, 40(31): 3576-3586. DOI:10.1200/JCO.22.01504.
[28] Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma[J]. Blood Adv, 2021, 5(8): 2196-2215. DOI:10.1182/bloodadvances.2020003805.
[29] Kodama T, Kochi Y, Nakai W, et al. Anti-GPRC5D/CD3 bispecific t-cell-redirecting antibody for the treatment of multiple myeloma[J]. Mol Cancer Ther, 2019, 18(9): 1555-1564. DOI:10.1158/1535-7163.MCT-18-1216.
[30] Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial[J]. Lancet, 2020, 395(10218): 132-141. DOI:10.1016/S0140-6736(19)32956-3.
[31] Chari A, Berdeja JG, Oriol A, et al. A phase 1, first-in-human study of talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)[J]. Blood, 2020, 136: 40-41. DOI:10.1182/blood-2020-133873.
[32] Jesus G, Amrita Y, Avbert Oriol, et al. Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM) [J]. J Clin Oncol, 2021, 39 15_suppl: 8088.
[33] Chari A, Hari P, Bahlis NJ, et al. Phase 1b results for subcutaneous talquetamab plus daratumumab in patients with relapsed/refractory multiple myeloma[J]. Blood, 2021, 138: 161. DOI:10.1182/blood-2021-148813.
[34] Li J, Stagg NJ, Johnston J, et al. Membrane-Proximal epitope facilitates efficient t cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing[J]. Cancer Cell, 2017, 31(3): 383-395. DOI:10.1016/j.ccell.2017.02.001.
[35] Cohen AD, Harrison SJ, Krishnan A, et al. Initial clinical activity and safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging bispecific antibody, in relapsed/refractory multiple myeloma[J]. Blood, 2020, 136 Suppl 1: 42-43. DOI:10.1182/blood-2020-136985.
[36] Trudel S, Cohen AD, Krishnan AY, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study[J]. Blood, 2021, 138: 157. DOI:10.1182/blood-2021- 147983.
[37] Teshima T. Create a healthy diet after transplant![J]. Blood, 2020, 136(1): 8-9. DOI:10.1182/blood. 2020006611.
[38] Mouhieddine TH, Van Oekelen O, Melnekoff DT, et al. Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients[J]. Blood Adv, 2022, 26: bloodadvances.2022007923. DOI:10.1182/bloodadvances.2022007923.
[39] Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma[J]. N Engl J Med, 2022, 387(6): 495-505. DOI:10.1056/NEJMoa2203478.
[40] Kakiuchi-Kiyota S, Ross T, Wallweber HA, et al. A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma[J]. Leukemia, 2022, 36(4): 1006-1014. DOI:10.1038/s41375-021-01478-w.